Cumulative effects of irreversible MAO inhibitors in vivo

The effects of repeated treatment with clorgyline, pargyline, deprenyl and tranylcypromine on MAO activity in rat brain and liver were investigated. MAO was measured with the substrates serotonin (5HT), phenethylamine (PEA) and, in some cases, t brain tissue after single and repeated administrations of 10 mg/kg s.c. clorgyline or deprenyl were also compared. Single doses of clorgyline (1 and 10 mg/kg s.c.) completely blocked the deamination of 5-HT. PEA deamination gradually decreased during the 14-day treatment. Pargyline in a dose of 0.3 mg/kg s.c. reduced both 5-HT and PEA deamination progressively over the same period. In the course of repeated treatment the effects of clorgyline and deprenyl on 5-HT and PEA deamination increased in intensity, by a factor of about 10 in the brain and about 3 in the liver. The potentiation of the effect of tranylcypromine was less marked (brain: × 4; liver: × 2). The rates of recovery of MAO activity were not greater after repeated than after single administrations of high doses of clorgyline and deprenyl, suggesting that the withdrawal of the drugs is not followed by a rebound phenomenon. Our results indicate that repeated treatment with suitable doses of clorgyline or deprenyl leads to specific reduction of either MAO A or B activity in brain, without producing any appreciable effect in the liver.     

Target size of 5-HT3 receptors in N1E-115 neuroblastoma cells and rat brain

Radiation inactivation was used to determine the molecular target size of the binding site for [3H]GR65630, a specific 5-HT3 receptor ligand, in two different neuronal tissues. Using a calibration curve of known molecular weight enzymes, the target sizes of [3H]GR65630 binding sites in N1E-115 neuroblastoma cells and rat brain were 98,600 +/- 11,300 and 49,100 +/- 8,500 Da, respectively. The results suggest 5-HT3 receptors may be present as dimers in N1E-115 neuroblastoma cells.     

Studies of monoamine oxidases: Inhibition of bovine brain MAO in intact mitochondria by selective inhibitors

The inhibition of mitochondrial monoamine oxidase (MAO) from beef brain cortex by the selective inhibitors, clorgyline, harmaline, Deprenyl and pargyline, was compared using five substrates: serotonin (5-HT), β-phenylethylamine (PEA), tyramine, tryptamine and dopamine. Dose-response studies, consistent with the classification of MAO, types A and B, indicated that serotonin deamination was more sensitive to clorgyline and harmaline inhibition than was phenylethylamine. However, the curves for all substrates were double-sigmoidal, rather than being a single sigmoid curve for 5-HT and PEA. Deprenyl and pargyline did not exhibit any marked selectivity for inhibiting PEA deamination without prior preincubation of enzyme and inhibitor. The rate of inhibition was variable and was dependent upon the substrate, the nature of the inhibitor and the inhibitor concentration. Dual inhibitor studies, using the “type A” inhibitor, clorgyline, and the “type B” inhibitor, Deprenyl, together, resulted in almost complete MAO inhibition, regardless of substrate. Combining the two type A inhibitors, clorgyline and harmaline, or the two type B inhibitors, deprenyl and pargyline, resulted in inhibitions that were equal to or only slightly greater than the inhibition produced by a single inhibitor. These results suggested that there are at least two distinct sites in beef brain MAO from cortical mitochondria which may be interacting. The deamination of all substrates occurs at both sites.     

Binding and deamination of various substrates by types A and B monoamine oxidase in bovine brain mitochondria

The binding and deamination of four substrates by type A and type B monoamine oxidase (MAO) in bovine brain mitochondria were investigated in mixed substrate experiments. MAO activity in bovine brain mitochondria, with 5-hydroxytryptamine (5-HT) as substrate, was highly sensitive to clorgyline and less sensitive to deprenyl, while MAO activity with benzylamine or β-phenylethylamine (PEA) as substrate was highly sensitive to deprenyl and less sensitive to clorgyline. On the other hand, when tyramine plus PEA was used as substrate, the inhibition curves of clorgyline and deprenyl were both biphasic. These results indicate that 5-HT and benzylamine were preferentially deaminated by type A MAO and type B MAO, respectively, and that tyramine and PEA were deaminated by both types of MAO. Studies on the inhibition by clorgyline plus deprenyl of tyramine deamination (in the absence and presence of another substrate) showed that the deamination of tyramine by both type A and type B MAO was inhibited by PEA or benzylamine, while only type A MAO was inhibited significantly by 5-HT. The KA_i value, the dissociation constant of the type A MAO and 5-HT complex, and the KB_i values, the dissociation constants of the type B MAO and PEA or benzylamine complex, were almost equal to the K_m values of type A MAO and type B MAO respectively. The KA_i values for PEA and benzylamine were 78 and 58 μM respectively. For the type B MAO-5-HT complex, the dissociation constant KB_i was 1447 μM. These results show that type A MAO deaminates tyramine and 5-HT whereas benzylamine is not deaminated, but only binds to the substrate binding site of type A MAO with almost the same rate as that for deamination by type B MAO; with type B MAO, tyramine, PEA and benzylamine are deaminated, whereas 5-HT is not deaminated and binds to the substrate binding site of type B MAO with low affinity.     

Substrate- and inhibitor-related characteristics of human platelet monoamine oxidase

Human platelet monoamine oxidase (MAO) preferentially deaminated benzylamine and phenylethylamine, two substrates relatively specific for type B MAO, in comparison to 5-hydroxytryptamine, a substrate specific for type A MAO. In studies comparing human platelet and rat brain MAO specific activities, benzylamine and 5-hydroxytryptamine deamination by platelets was approximately 90 and 2 per cent, respectively, that of brain, while platelet deamination of dopamine, tryptamine and tyramine was 20 per cent or less than that of brain. Among sixteen drugs studied, platelet MAO activity was selectively inhibited by low concentrations of the MAO-B inhibitors, deprenyl and pargyline, and was relatively insensitive to the MAO-A inhibitors, clorgyline and Lilly 51641. These observations, in addition to the simple sigmoid inhibition curves obtained with increasing concentrations of either clorgyline or deprenyl, suggest that platelet MAO consists of essentially one distinguishable form of MAO which most closely resembles the MAO type B found in other tissues.     

Studies of monoamine oxidases. Inhibition of bovine brain MAO in intact mitochondria by tricyclic antidepressant drugs.

Tricyclic antidepressant drugs (TCA) were found to reversibly inhibit monoamine oxidase (MAO) in intact mitochondria of beef brain cortex, I₅₀, values were in the range of 10^?4 to 10^?3 M, using chlorimipramine, amitriptyline, desimipramine, imipramine and doxepin. Unlike TCA inhibition reported for MAO in rabbit tissues, the inhibition observed with beef brain MAO was greater for the A-type enzyme, indicated by serotonin (5-HT) deamination, than for the B-type enzyme, indicated by phenylethylamine (PEA) deamination. Chlorimipramine was the most effective of the five tricyclic antidepressant drugs tested for the inhibition of 5-HT deamination, while amitriptyline was the most effective for inhibiting PEA deamination. Kinetic analyses also revealed marked differences in the interaction of the tricyclics with the A form and the B form of MAO. Inhibition was found to be of a mixed type by reciprocal plots, but Dixon plots indicated that the inhibition was parabolic with 5-HT and either linear or hyperbolic with PEA, depending on the TCA used. Mixed inhibitor studies were also carried out, combining a TCA with a selective (clorgyline or deprenyl) or a non-selective (tranylcypromine) MAO inhibitor. Such combinations did not result in a potentiation of inhibition of either the MAO-A or MAO-B type enzyme activity. The present results indicate that the inhibition of MAO may be of only minor significance in the therapeutic efficacy of TCA in the treatment of depression, especially in combined therapy. However, this conclusion must be tempered by the knowledge that there are marked variations in MAO properties from different enzyme sources, as evidenced by these results.     

The properties of 5-HT3 receptors in clonal cell lines studied by patch-clamp techniques.

1 The characteristics of transmembrane currents evoked by 5-hydroxytryptamine (5-HT) in the neuroblastoma x Chinese hamster brain cell line NCB-20 and neuroblastoma clonal cell line N1E-115 have been studied under voltage-clamp conditions by the whole-cell recording and outside-out membrane patch modes of the patch-clamp technique. 2 In 73% of NCB-20 cells examined (n = 221), and all N1E-115 cells studied (n = 80), 5-HT (10 microM) elicited a transient inward current at negative holding potentials, this being associated with an increase in membrane conductance. In both cell lines responses to 5-HT reversed in sign at a potential of approximately -2 mV and demonstrated inward rectification. 3 The reversal potential of 5-HT-induced currents (E5-HT) recorded from either NCB-20 or N1E-115 cells was unaffected by total replacement of internal K+ by Cs+. In N1E-115 cells, reducing internal K+ concentration from 140 to 20 mM produced a positive shift in E5-HT of approximately 28 mV, whereas reducing external Na+ from 143 to 20 mM was associated with a negative shift in E5-HT of about 37 mV. A large reduction in internal Cl- concentration (from 144 to 6 mM) had little effect on E5-HT. 4 5-HT-induced currents of NCB-20 cells were unaffected by methysergide (1 microM) or ketanserin (1 microM), but were reversibly antagonized by GR38032F (0.1-1.0 nM) with an IC50 of 0.25 nM. GR 38032F (0.3 nM) reduced 5-HT-induced currents in N1E-115 cells to approximately 26% of their control value. 5 On outside-out membrane patches excised from both NCB-20 and N1E-115 cells, 5-HT induced small inward currents which could not be clearly resolved into discrete single channel events. Such responses were: (i) reversibly antagonized by GR 38032F (1 nM) (ii) reversed in sign at 0 mV, and (iii) subject to desensitization. 6 Fluctuation analysis of inward currents evoked by 5-HT (1 microM) in N1E-115 cells suggests that 5-HT gates a channel with a conductance of approximately 310fS. Such a relatively small conductance could readily explain why the response of outside-out membrane patches to 5-HT cannot at present be resolved into clear single channel events.     

Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain

Cortex and caudate specimens from human, non-human primate and rodent brains were examined for their ability to deaminate dopamine and for their sensitivity to irreversible monoamine oxidase (MAO) inhibitors. Using inhibition curves obtained with clorgyline, deprenyl and pargyline to estimate the relative proportions of MAO-A and MAO-B activity, dopamine was found to be deaminated predominantly by MAO-A in rat cortex and caudate. In contrast, dopamine was primarily an MAO-B substrate in human and vervet cortex and caudate. When clorgyline inhibition curves with tyramine or dopamine as substrate were compared in human, vervet and rat cortex, more pronounced species differences were found with dopamine than with tyramine. In all three species caudate tended to be more sensitive to inhibition by low concentrations of clorgyline than was cortex, suggesting a higher proportion of MAO-A activity in caudate. Similar species differences were also found when MAO-A activities were estimated using serotonin (5-HT): -phenylethylamine (PEA) ratios (5-HT/5-HT + PEA). These ratios with selective substrates were highly correlated with clorgyline inhibition curves obtained with tyramine as substrate across 29 brain regions and tissues from different rodent and primate species (r=0.85, P<0.001). Data from both the substrate ratios and the clorgyline inhibition curves confirmed the relative predominance of MAO-B activity in primate brain regions (70–85%) as compared to rat brain regions (45%). Smaller species differences were observed in liver. Species differences in the proportion of brain MAO-A and B activities and in the deamination of dopamine and other substrates for MAO may have important implications in regard to the widespread use of rodent rather than primate models in the study of biogenic amine metabolism and of drugs affecting amine function.     

5-HT3 receptors in NG108-15 neuroblastoma x glioma cells: effect of the novel agonist 1-(m-chlorophenyl)-biguanide.

The effect of the novel agonist, 1-(m-chlorophenyl)-biguanide (mCPBG) was examined on 5-HT3 receptors in NG108-15 mouse neuroblastoma x rat glioma hybrid cells, using whole-cell voltage-clamp and radioligand binding on intact cells. Electrophysiological studies showed that mCPBG is a partial agonist, with an EC50 of 3.1 microM. Displacement of the selective 5-HT3 receptor antagonist [3H]GR65630 by mCPBG revealed a Ki of 14.2 nM. The study suggests that mCPBG may have a high affinity for desensitized 5-HT3 receptors and also revealed some differences between 5-HT3 receptors in NG108-15 and N1E-115 cells.     

Substrate specificity and inhibitor sensitivity of monoamine oxidase in rat kidney mitochondria.

The deamination of the substrates 5-hydroxytryptamine (5-HT), tyramine, dopamine, β-phenylethylamine and benzylamine by rat kidney mitochondrial monoamine oxidase (MAO) was studied, and kinetic constants are reported for each substrate. By the use of the selective MAO inhibitors, clorgyline and deprenyl, 5-HT and benzylamine were found to be substrates for types A and B MAO, respectively, in this tissue, whereas the other substrates were metabolized by both forms of MAO. No evidence for any significant metabolism of 5-HT or benzylamine by other amine oxidases was obtained. However, some conditions under which the carbonyl reagents semicarbazide, isoniazid and aminoguanidine may interfere with assays for MAO, without actually affecting enzyme activity directly, are described. Preincubation of kidney mitochondria with histamine resulted in a time- and oxygen-dependent irreversible inhibition of both type A and type B MAO activity; the exact nature of the inhibitory agent and its mode of action remain to be determined.     

Inhibition of mitochondrial monoamine oxidase of the rat uterus and liver by clorglyine, pargyline and harmine.

The inhibition of mitochondrial monoamine oxidase (MAO) activity in rat uterus and liver by clorgyline, harmine and pargyline is reported. MAO activity is shown to be present in mitochondria of the rat uterus by rate-zonal centrifugation on a sucrose gradient. Each inhibitor was tested for its ability to inhibit the oxidation of tyramine (TYN). 5-hydroxytryptamine (5HT) and β-phenylethylamine (PEA). TYN deamination by uterine organelles was inhibited in two distinct steps by clorgyline and harmine, whereas in liver mitochondria only clorgyline manifested the two-step inhibition pattern. Elimination of TYN oxidation by pargyline occurred as a single sigmoid curve. Single sigmoid inhibition curves with all three inhibitors were also observed for 5HT and PEA in both tissues. For uterine and liver mitochondria the relative effectiveness of each inhibitor toward the oxidation of the three substrates was as follows: (a) clorgyline and harmine. 5HT > TYN > PEA; (b) pargyline. PEA > TYN > 5HT. It was concluded that, as has been previously demonstrated in liver, two forms of MAO exist in mitochondria isolated from the rat uterus. This conclusion is based upon (1) the biphasic inhibition of TYN deamination by clorgyline and harmine and (2) the reversal of the relative inhibitory effectiveness of the two classes of MAO inhibitors, (a) clorgyline and harmine and (b) pargyline, toward the three substrates. Semicarbazide did not inhibit the oxidation of any of the substrates. This indicates that the mitochondrial enzyme activity from the uterus, as in the liver, is a true monoamine oxidase.     

Comparative studies of the effects of RS-8359 and safrazine on monoamine oxidase in-vitro and in-vivo in mouse brain

The effect of RS-8359, pyrimidine on monoamine oxidase (MAO) has been compared with a hydrazinic MAO inhibitor, safrazine (beta-piperonylisopropylhydrazine hydrochloride,) which is a MAO inhibitor used clinically. In-vitro radiochemical determination of MAO activity showed that the IC50 of RS-8359 was 0.52 microM for the deamination of 5-hydroxytryptamine (5-HT) in the mouse brain mitochondrial preparation, while beta-phenylethylamine (PEA) deamination was inhibited by only 20% at 100 microM of the drug. 5-HT deamination in the brain homogenate prepared from mice killed 60 min after administration of RS-8359 was inhibited significantly by 14 and 48%, at 30 and 100 mg kg-1 (p.o.), respectively, while deamination of PEA was little affected at the same doses. On the other hand, safrazine strongly inhibited both 5-HT and PEA deaminations, but showed no selectivity toward the substrate used. The extent of MAO inhibition by RS-8359, measured fluorometrically with kynuramine as a substrate in the brain homogenate, was independent of preincubation up to 80 min. In contrast, the inhibitory potency of safrazine was strengthened by preincubation in a time-dependent manner. Oral administration of RS-8359 (3-30 mg kg-1) caused a dose-dependent increase in endogenous monoamines in mouse brain, which disappeared a few hours after its administration. Increase in monoamine content caused by safrazine lasted for at least 24 h. These results indicate that RS-8359 is a reversible and specific inhibitor of MAO-A, while safrazine is an irreversible and non-specific MAO inhibitor, in-vivo and in-vitro in mouse brain.     

Pharmacological differences and similarities between the native mouse 5-HT3 receptor in N1E-115 cells and a cloned short splice variant of the mouse 5-HT3 receptor expressed in HEK 293 cells

Human embryonic kidney (HEK) 293 cells were stably transfected with the cDNA encoding the short splice variant of the mouse 5-HT3 receptor (m5-HT3A(b); isolated by RT-PCR from NG108-15 cells) and its pharmacological properties were compared with those of the native 5-HT3 receptor of the mouse neuroblastoma cell line N1E-115. The m5-HT3A(b) receptor of N1E-115 cells differs from that isolated from NG108-15 cells by one amino acid (Val instead of Ile) at position 52 of the amino acid sequence. Both radioligand binding studies with the selective 5-HT3 receptor antagonist [3H]GR65630 (3-(5-methyl-1H-imidazol-4-yl)-1-(1-methyl-1H-indol-3-yl)-1-propanone) and functional experiments by measurement of [14C]guanidinium influx evoked by 5-HT in the absence and presence of 10 microM substance P were carried out. Binding of [3H]GR65630 to the recombinant receptor in HEK 293 cells and the native receptor in N1E-115 cells was specific and of high affinity (Kd 4.4 and 3.0 nM, respectively) and characterized by Bmax values of 875 and 1414 fmol/mg protein, respectively. At 10 nM [3H]GR65630, specific binding was inhibited by the selective 5-HT3 receptor antagonist ondansetron (Ki 11 and 42 nM, respectively) and by 5-HT (Ki 294 and 563 nM, respectively). In the transfected HEK 293 cells, 5-HT induced an influx of [14C]guanidinium both in the absence (pEC50 5.7) and presence of substance P (pEC50 6.6,) which was counteracted by 0.3 microM ondansetron; in the N1E-115 cells, 5-HT also evoked [14C]guanidinium influx in the absence (pEC50 6.0) and presence of substance P (pEC50 6.0). Both in transfected HEK 293 cells and in N1E-115 cells, the 5-HT receptor ligand RS-056812-198 ((R)-N-(quinuclidin-3-yl)-2-(1-methyl-1 H-indol-3-yl)-2-oxo-acetamide; in the presence of substance P) induced an influx of [14C]guanidinium (pEC50 9.8 and 8.7, respectively) with a maximum of about 70 and 30% of the maximum response to 5-HT, respectively. 5-HT (in the presence of substance P)-induced [14C]guanidinium influx was inhibited by the imidazoline BDF 6143 (4-chloro-2(2-imidazolin-2-ylamino)-isoindoline; pIC50 4.9 and 5.3, respectively) and by the sigma-site ligand (+/-)-ifenprodil (pIC50 5.0 and 5.2, respectively). In conclusion, most of the drugs exhibited practically identical properties at both the recombinant m5-HT3A(b) receptor in HEK 293 cells and the native m5-HT3 receptor of N1E-115 cells. However, the recombinant receptor had a higher affinity for ondansetron, and the potency of 5-HT in inducing cation influx through the recombinant, but not through the native receptor, was increased by substance P. RS-056812-198 was a 10-fold more potent partial agonist at the recombinant than at the native receptor. These differences may be due to cell-specific post-translational modifications of the 5-HT3 receptor protein in the two cell lines, to the expression of other subunits in addition to the m5-HT3A(b) receptor in N1E-115 cells and/or to the difference in the amino acid sequence at position 52 of the short splice variants of the m5-HT3 receptors expressed in the two cell lines.     

Benzylhydrazine--a selective inhibitor of human and rat brain monoamine oxidase.

Benzylhydrazine (BzNNH₂) was shown to inhibit irreversibly human brain type A and type B monoamine oxidase (MAO) as measured by 5-hydroxytryptamine (5-HT) and phenylethylamine (PEA) deamination, respectively. The concentrations required to inhibit these isoenzymes in vitro were 2.7 × 10^?7M and 1.7 × 10^?8M, respectively. Inhibition of 5-HT deamination was essentially non-competitive, whereas that for PEA approached uncompetitive kinetics. BzNNH₂ also inhibited rat brain MAO in vivo, 50 per cent inhibition of the A and B forms of MAO occurring at injected doses of 0.72 and 0.39 mg/kg respectively. These results indicate that BzNNH₂ preferentially inhibits the B form of both human and rat brain MAO.     

Monoamine oxidase inhibitors increase preferentially extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in the awake rat

Summary We have examined the local and systemic effects of clorgyline, tranylcypromine and deprenyl on extracellular serotonin (5-HT) and 5-hydroxyindoleacetic acid in the raphe nuclei and in frontal cortex of awake, freely-moving rats using microdialysis. When administered through the dialysis probe, monoamine oxidase (monoamine: oxygen oxidoreductase (deaminating), E.C. 1.4.3.4., MAO) inhibitors increased 5-HT output in a dose-dependent manner in both brain areas. The effects were more pronounced in the raphe nuclei for the three MAO inhibitors at all doses assayed.When the monoamine oxidase inhibitors were given i.p., dialysate 5-HT increased dramatically, after tranylcypromine (15 mg/kg), in raphe nuclei and frontal cortex (area under the curve (AUC) to 4 h post-treatment: 63-fold and 11-fold, respectively) whereas the effects of clorgyline (10 mg/kg) were much less pronounced (+ 47% increase in the AUC for raphe nuclei, P < 0.09; + 18% increase in the AUC for frontal cortex, n.s.). Deprenyl (2.5 mg/kg, i.p.) induced a moderate (+ 22%) increase of dialysate 5-HT from the raphe nuclei but did not cause a change in dialysate 5-HT from the frontal cortex (+ 4%). However, clorgyline, or deprenyl, dramatically increased dialysate 5-HT in animals which had been pre-treated with the above dose of deprenyl, or clorgyline, respectively, showing that the blockade of both forms of MAO results in much larger increases of extracellular 5-HT than does the blockade of either form alone.These results indicate that: (a) deamination by MAO participates actively in the control of the extracellular concentration of 5-HT in those areas of the brain that are rich in serotoninergic nerve terminals as well as in cell bodies, (b) in vivo, brain 5-HT is deaminated preferentially by MAO-A but its full inhibition does not result in an increased release of 5-HT, in spite of a large accumulation of 5-HT in the brain tissue, (c) MAO-B deaminates 5-HT when the A-form is inhibited (in this situation, MAO-B participates actively in the control of a releasable pool of 5-HT), (d) the raphe nuclei appears to be a preferential site of action of MAO inhibitors, administered either locally or systemically. These results may help to understand the model of action of MAO inhibitors as antidepressant drugs.Correspondence to F. Artigas at the above address     

GEA 857 blocks potassium channels in the membrane and, thereby, prolongs muscarinic cholinergic responses in N1E-115 neuroblastoma cells.

GEA 857 [2-(4-chlorophenyl)-1,1-dimethylethyl 2-amino-3-methylbutanoate], a structural analogue of the serotonin (5-HT) uptake inhibitor alaprocalate but without effects on the 5-HT uptake, was shown to potentiate muscarinic cholinergic responses in N1E-115 neuroblastoma cells. In intracellular recording experiments, GEA 857 (1 microM) increased the cell input resistance and prolonged the action potential. It also prolonged the cellular response to carbachol acting on muscarinic receptors in a manner mimicked by potassium channel blockers such as 4-aminopyridine and TEA. GEA 857 did not affect the carbachol stimulated uptake of 45Ca, but depressed the carbachol activated outflow of 86Rb from neuroblastoma cells. The conclusion drawn from these results is that GEA 857 reduces potassium conductances in the membrane in N1E-115 neuroblastoma cells and, thereby, prolongs muscarinic agonist-induced responses.     

Biochemical evidence for somatostatin receptors in murine neuroblastoma clone N1E-115

Radioligand binding and functional assays were employed to demonstrate the existence of somatostatin receptors in the murine neuroblastoma clone N1E-115. Saturation experiments with [125I][Tyr11]somatostatin-14 indicated the presence of a single class of binding sites in membranes prepared from N1E-115 cells (Kd = 83 pM; Bmax = 21,000 receptors/cell). Somatostatin-14, somatostatin-28 and L363586 (cyclo(N-Me-ALA-TYR-D-TRP-LYS-VAL-PHE] all displaced the 125I-ligand monophasically in N1E-115 cells (Ki values were 28, 82 and 34 pM, respectively), which contrasted with the binding heterogeneity apparent with L363586 in rat brain membranes. The binding of [125I][Tyr11]somatostatin-14 was reduced by GppNHp, indicating that N1E-115 somatostatin receptors interacted with guanine nucleotide binding protein(s). Somatostatin agonists decreased by 30-50% the levels of [3H]cyclic AMP induced in intact cells by forskolin, prostaglandin E1, or vasoactive intestinal polypeptide. The EC50 values for inhibition of the [3H]cyclic AMP response to PGE1 by L363586, somatostatin-14, and somatostatin-28 were 0.24, 0.63 and 1.0 nM, respectively. Pertussis toxin treatment of N1E-115 cells reduced both binding to the receptor and the functional response to somatostatin-14. These data suggest that a single class of somatostatin receptors in N1E-115 cells are linked to the inhibition of adenylate cyclase through a Gi protein.     

GEA 857 Blocks Potassium Channels in the Membrane and,Thereby, Prolongs Muscarinic Cholinergic Responses in N1E-115 Neuroblastoma Cells

Abstract: GEA 857 [2-(4-chlorophenyl)-1,1-dimethylethyl 2-amino-3-methylbutanoate], a structural analogue of the serotonin (5-HT) uptake inhibitor alaproclate but without effects on the 5-HT uptake, was shown to potentiate muscarinic cholinergic responses in N1E-115 neuroblastoma cells. In intracellular recording experiments, GEA 857 (1 μM) increased the cell input resistance and prolonged the action potential. It also prolonged the cellular response to carbachol acting on muscarinic receptors in a manner mimicked by potassium channel blockers such as 4-aminopyridine and TEA. GEA 857 did not affect the carbachol stimulated uptake of ⁴⁵Ca, but depressed the carbachol activated outflow of ⁸⁶Rb from neuroblastoma cells. The conclusion drawn from these results is that GEA 857 reduces potassium conductances in the membrane in N1E-115 neuroblastoma cells and, thereby, prolongs muscarinic agonist-induced responses.     

A comparison of the pharmacological and biochemical properties of substrate-selective monoamine oxidase inhibitors

1. M&B 9302, E-250, NSD 2023, and Lilly 51641, substrate-selective inhibitors of monoamine oxidase (MAO), and two non-selective inhibitors of MAO (tranylcypromine and phenelzine) have been compared in the rat for activity in (i) inhibiting rat brain monoamine oxidase in vitro and in vivo using tyramine, 5-hydroxytryptamine (5-HT) and benzylamine as substrates; (ii) increasing brain levels of noradrenaline (NA) and 5-HT and (iii) antagonizing tetrabenazine-induced sedation.2. Concentrations of M&B 9302 and Lilly 51641 required to produce 50% inhibition of 5-HT oxidation by brain mitochondrial MAO were 1.4 x 10(-8)M and 2.5 x 10(-7)M respectively. Higher concentrations were required to inhibit tyramine oxidation whilst benzylamine oxidation was inhibited only at concentrations above 10(-5)M.3. E-250 showed the reverse substrate-selectivity in inhibiting the oxidation of benzylamine at concentrations below that required to inhibit the oxidation of 5-HT. NSD 2023 showed little substrate selectivity in vitro.4. Qualitatively similar results were obtained in vivo, except that NSD 2023 showed more marked substrate-selectivity.5. All the inhibitors except E-250 produced a dose-related rise in brain 5-HT levels. Only phenelzine and Lilly 51641 showed a linear relationship between NA levels and dose.6. All the drugs antagonized, in dose-related fashion, the effects of tetrabenazine in reducing locomotor activity. E-250 and NSD 2023 failed to restore locomotor activity to control levels whilst in high doses the other inhibitors, when given before tetrabenazine, produced a considerable increase in locomotor activity.7. Antagonism of tetrabenazine sedation appears to be correlated with (a) inhibition of the enzyme species that oxidize 5-HT and NA but not with inhibition of the enzyme species that oxidize benzylamine; (b) the rise in brain 5-HT levels rather than NA levels.     

The effect of selective type A or type B monoamine oxidase inhibition on the intrasynaptosomal deamination of (3H)serotonin in rat spinal cord tissue

Summary The degree to which the type A and type B forms of monoamine oxidase participate in the intraneuronal deamination of (³H)serotonin (5-HT) was examined in synaptosomal-rich fractions of rat spinal cord tissue. Synaptosomes were labeled with (³H)5-HT and superfused with physiological buffers containing selective concentrations of a type A (clorgyline) or a type B (deprenyl) MAO inhibitor. The efflux of (³H)5-HT and newly-formed (³H)5-hydroxyindoleacetic acid (5-HIAA) was determined and compared to controls over time. In control samples, a slight decline in (³H)5-HT efflux occurred over the experimental superfusion period. However, a stable formation and efflux of (³H)5-HIAA was seen during this same period of time. When clorgyline was added to the superfusion buffer, a rapid decline in superfusate levels of (³H)5-HIAA was observed. Similar experiments in the presence of deprenyl were without effect. In order to elevate cytoplasmic concentrations of (³H)5-HT and therefore increase its chances for interaction with nerve terminal MAO, reserpine was added to the superfusion buffer. Reserpine caused a greater than 3-fold increase in (³H)5-HIAA formation with no change in (³H)5-HT efflux. Clorgyline inhibited this increase in (³H)5-HIAA formation but deprenyl was again without effect. In the presence of clorgyline, reserpine also caused an increase in (³H)5-HT efflux. These results strongly support the notion that 5-HT deamination within rat spinal cord nerve terminals occurs primarily, if not exclusively, through an interaction with type A MAO.Abbreviations 5-HT 5-hydroxytryptamine, serotonin - MAO monoamine oxidase - 5-HIAA 5-hydroxyindoleacetic acid Supported in part by N.I.H. grants GM 30002, 5-T32-GM 07039, and the West Virginia University Medical Corporation. L. M. B. was supported by a Swiger Fellowship